Introduction

Eli Lilly reported stronger-than-expected Q3 2026 results, driven by continued demand for its flagship GLP-1 therapies Zepbound and Mounjaro. The company lifted its full-year revenue forecast, signaling confidence in the expanding obesity and diabetes market.

What Happened

The pharmaceutical giant posted adjusted earnings of $7.48 per share on revenue of $24.40 billion, both surpassing analyst estimates. Zepbound generated $5.35 billion in quarterly sales, up 49% year-over-year, while Mounjaro reached $10.72 billion worldwide, a 65% increase. Despite the strong performance, the newly launched oral obesity pill Foundayo fell short of expectations, bringing in $184 million against projected $229 million. Lilly also announced plans to acquire Merida Biosciences, expanding its pipeline beyond metabolic disease. CEO Dave Ricks emphasized the "dramatic" room for growth in the obesity care market, noting the company's dominant 63% U.S. market share.

Why This Matters

The results highlight Lilly's continued momentum in the highly competitive GLP-1 space, where it outpaces rival Novo Nordisk in U.S. market share. The raised guidance—now projecting $91 billion to $92 billion in 2026 revenue—reflects not only strong quarterly results but also the broader shift in healthcare toward weight-loss and diabetes treatments. With Medicare beginning temporary coverage of GLP-1s for weight loss and Lilly's pipeline expanding into autoimmune and allergic diseases, the company is positioning itself as a central player in next-generation therapeutics. Ricks' comment that market expansion is "dramatic" underscores the scale of opportunity ahead.

Key Takeaways

Eli Lilly raised its 2026 revenue outlook to $91–$92 billion, up from prior $85–$87 billion guidance. Zepbound and Mounjaro delivered robust double-digit growth, reinforcing Lilly's leadership in the GLP-1 class. Foundayo's debut missed estimates, but the company expects broader diabetes approval and doubled patient uptake. Lilly's U.S. market share reached 63% for obesity and diabetes drugs, compared to Novo's 36.6%. The acquisition of Merida Biosciences signals a strategic move into autoimmune and allergic disease treatments. CEO Dave Ricks described the obesity market expansion as "dramatic," suggesting further growth potential as access widens.

Conclusion

Eli Lilly's Q3 2026 results reinforce its position as a dominant force in the booming obesity and diabetes drug market. With a raised revenue forecast, strong product performance, and strategic acquisitions, the company is poised to capitalize on what executives call a dramatically expanding therapeutic landscape. As access widens and new indications emerge, Lilly's trajectory suggests continued influence over the future of metabolic disease treatment.